About this trial
Vestibular migraine is a phenotype of migraine, characterized by more prominent vertigo symptoms compared to headache. Treatments for VM are mainly divided into two categories: acute treatment and preventive treatment. Acute treatment aims to reduce the severity and duration of a single episode, while preventive treatment aims to decrease the frequency, severity, and duration of attacks. Current acute treatments are primarily divided into pain relief and anti-dizziness, with specific drugs such as triptans and ergots being applicable for pain relief, but only betahistine has weak evidence for anti-dizziness, and relevant clinical evidence is very scarce. Preventive treatment mainly refers to migraine preventive treatments, with recommended medications including traditional drugs like topiramate, flunarizine, propranolol, etc., but the efficacy and safety of these drugs are limited. CGRP-targeted drugs are believed to play a role in the preventive treatment of VM, and there are related literature reports, but most are small-sample studies or retrospective studies. This study aims to explore the real-world efficacy of CGRP-targeted drugs in the acute and preventive treatment of VM through a prospective real-world study.
Eligibility criteria
Qualifiers
Male or female, aged between 18 and 75 years.
More than or equal to 4 days per month with confirmed vestibular symptom in the three months prior to enrollment (only required for group B).
Able to complete at least 80% of the electronic diary during the treatment period.
The investigator believes that the participant is able to read, understand, and complete the study questionnaires and headache diary.
Disqualifiers
Pregnant women, breastfeeding women, or those unwilling to use approved contraceptive methods during study participation.
Presence of a condition or abnormality that the investigator believes would affect the safety of the patient or the quality of the data.
History of ear surgery (excluding ear tube surgery).
Other vestibular diagnoses (excluding treated benign paroxysmal positional vertigo, BPPV). This includes Ménière's disease, superior semicircular canal dehiscence syndrome, vestibular neuritis, persistent postural-perceptual dizziness, unilateral or bilateral vestibular hypofunction, cerebellar or brainstem disorders, multiple sclerosis, or seasickness.
Trial design
Treatments tested in this trial
- CGRP R Inhibitor; CGRP Inhibitor
- none-CGRP
Treatment groups
Locations
Sponsors and collaborators
Second Affiliated Hospital, School of Medicine, Zhejiang University
Lead sponsor
First People's Hospital of Hangzhou
Collaborator
Sir Run Run Shaw Hospital
Collaborator
Affiliated Hospital of Jiaxing University
Collaborator
The People's Hospital of Quzhou
Collaborator
The First People Hospital of Hangzhou Lin An District
Collaborator
Shaoxing People's Hospital
Collaborator
Jiaxing Hospital of T.C.M
Collaborator
Hangzhou Hospital of Traditional Chinese Medicine
Collaborator
Affiliated Wenling Hospital of Wenzhou Medical University
Collaborator
First Affiliated Hospital of Wenzhou Medical University
Collaborator
Second Affiliated Hospital of Wenzhou Medical University
Collaborator
Zhongshan Hospital Of Traditional Chinese Medicine
Collaborator
The First People's Hospital of Huzhou
Collaborator
Xin Hua Hospital of Zhejiang Province
Collaborator
The Affiliated Hospital of Hangzhou Normal University
Collaborator
Huzhou Central Hospital
Collaborator
Chinese Medical University
Collaborator
Tiantai County People's Hospital
Collaborator
Zhejiang University
Collaborator